Hiroyuki Seimiya

List of Publications by Year
in descending order

99 papers	4,635 citations	126907 33 h-index	102487 66 g-index
101 all docs	101 docs citations	101 times ranked	6790 citing authors

#	Article	IF	Citations
1	Role of EMT in the DNA damage response, doubleâ€strand break repair pathway choice and its implications in cancer treatment. Cancer Science, 2022, , .	3.9	4
2	Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1Î±. Bioorganic and Medicinal Chemistry, 2021, 30, 115949.	3.0	3
3	Gâ€quadruplexâ€forming nucleic acids interact with splicing factor 3B subunit 2 and suppress innate immune gene expression. Genes To Cells, 2021, 26, 65-82.	1.2	10
4	Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. International Journal of Colorectal Disease, 2021, 36, 131-139.	2.2	3
5	Novel tankyrase inhibitors suppress TDP-43 aggregate formation. Biochemical and Biophysical Research Communications, 2021, 537, 85-92.	2.1	4
6	Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Science, 2021, 112, 1963-1974.	3.9	13
7	Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. Scientific Reports, 2021, 11, 15125.	3.3	8
8	Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. Journal of Antibiotics, 2021, 74, 617-628.	2.0	10
9	Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
10	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. Investigational New Drugs, 2020, 38, 111-119.	2.6	6
11	Tankyrase promotes primary precursor miRNA processing to precursor miRNA. Biochemical and Biophysical Research Communications, 2020, 522, 945-951.	2.1	3
12	Target identification of a macrocyclic hexaoxazole G-quadruplex ligand using post-target-binding visualization. Chemical Communications, 2020, 56, 12905-12908.	4.1	17
13	Crossroads of telomere biology and anticancer drug discovery. Cancer Science, 2020, 111, 3089-3099.	3.9	28
14	Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer. Journal of Medicinal Chemistry, 2020, 63, 4183-4204.	6.4	25
15	A fully synthetic 6-aza-artemisinin bearing an amphiphilic chain generates aggregates and exhibits anti-cancer activities. Organic and Biomolecular Chemistry, 2020, 18, 5339-5343.	2.8	10
16	Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Science, 2020, 111, 441-450.	3.9	8
17	ALDH1A3â€mTOR axis as a therapeutic target for anticancer drugâ€tolerant persister cells in gastric cancer. Cancer Science, 2020, 111, 962-973.	3.9	36
18	Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase. Molecular Cancer Therapeutics, 2020, 19, 765-776.	4.1	14

#	Article	IF	Citations
19	G-quadruplex in cancer biology and drug discovery. Biochemical and Biophysical Research Communications, 2020, 531, 45-50.	2.1	48
20	c-KIT regulates stability of cancer stemness in CD44-positive colorectal cancer cells. Biochemical and Biophysical Research Communications, 2020, 527, 1014-1020.	2.1	7
21	In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. British Journal of Cancer, 2019, 121, 846-856.	6.4	13
22	Revisiting Telomere Shortening in Cancer. Cells, 2019, 8, 107.	4.1	98
23	Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 3407-3427.	6.4	43
24	From the wings to the center stage of chromosomes. Journal of Biological Chemistry, 2019, 294, 17723-17724.	3.4	3
25	Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. Scientific Reports, 2018, 8, 16756.	3.3	10
26	Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. Scientific Reports, 2018, 8, 14827.	3.3	17
27	<scp>RK</scp>â€287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Science, 2018, 109, 4003-4014.	3.9	60
28	Development of G-quadruplex ligands for selective induction of a parallel-type topology. Organic and Biomolecular Chemistry, 2018, 16, 7375-7382.	2.8	18
29	MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs. Oncotarget, 2018, 9, 35844-35855.	1.8	15
30	Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion. Cancer Research, 2017, 77, 2328-2338.	0.9	33
31	APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. Molecular Cancer Therapeutics, 2017, 16, 752-762.	4.1	67
32	Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. Scientific Reports, 2017, 7, 3605.	3.3	40
33	mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget, 2017, 8, 47902-47915.	1.8	20
34	Tankyrases. , 2017, , 4446-4449.		0
35	Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget, 2016, 7, 34811-34823.	1.8	43
36	Recent advances in telomere biology for new cancer medicine. Annals of Oncology, 2016, 27, vii70.	1.2	0

#	Article	IF	Citations
37	Design, Synthesis and Evaluation of an L-Dopa-Derived Macrocyclic Hexaoxazole (6otd) as a G-Quadruplex-Selective Ligand. Heterocycles, 2016, 92, 305.	0.7	3
38	Report on the use of nonâ€clinical studies in the regulatory evaluation of oncology drugs. Cancer Science, 2016, 107, 189-202.	3.9	6
39	Senescence from glioma stem cell differentiation promotes tumor growth. Biochemical and Biophysical Research Communications, 2016, 470, 275-281.	2.1	24
40	G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells. Biochemical and Biophysical Research Communications, 2016, 471, 75-81.	2.1	30
41	Design and Synthesis of a Berberine Dimer: A Fluorescent Ligand with High Affinity towards Gâ€Quadruplexes. Chemistry - A European Journal, 2015, 21, 14519-14528.	3.3	28
42	Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. Cancer Science, 2015, 106, 909-920.	3.9	18
43	Telomeric repeat-containing RNA/G-quadruplex-forming sequences cause genome-wide alteration of gene expression in human cancer cells in vivo. Nucleic Acids Research, 2015, 43, 2022-2032.	14.5	62
44	Predicting Risk at the End of the End: Telomere G-tail as a Biomarker. EBioMedicine, 2015, 2, 804-805.	6.1	4
45	Reprogramming Suppresses Premature Senescence Phenotypes of Werner Syndrome Cells and Maintains Chromosomal Stability over Long-Term Culture. PLoS ONE, 2014, 9, e112900.	2.5	52
46	TRF1 Ensures the Centromeric Function of Aurora-B and Proper Chromosome Segregation. Molecular and Cellular Biology, 2014, 34, 2464-2478.	2.3	29
47	Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. International Journal of Cancer, 2014, 135, 37-47.	5.1	52
48	TRIB1 Supports Prostate Tumorigenesis and Tumor-Propagating Cell Survival by Regulation of Endoplasmic Reticulum Chaperone Expression. Cancer Research, 2014, 74, 4888-4897.	0.9	53
49	Fission Yeast Pot1 and RecQ Helicase Are Required for Efficient Chromosome Segregation. Molecular and Cellular Biology, 2014, 34, 2551-2552.	2.3	0
50	Tankyrases. , 2014, , 1-4.		0
51	Interaction of long telomeric DNAs with macrocyclic hexaoxazole as a G-quadruplex ligand. MedChemComm, 2013, 4, 260-264.	3.4	7
52	Inhibition of ATP Citrate Lyase Induces an Anticancer Effect via Reactive Oxygen Species. American Journal of Pathology, 2013, 182, 1800-1810.	3.8	44
53	Telomere Length Influences Cancer Cell Differentiation In Vivo. Molecular and Cellular Biology, 2013, 33, 2988-2995.	2.3	45
54	Development of a gene expression database and related analysis programs for evaluation of anticancer compounds. Cancer Science, 2013, 104, 360-368.	3.9	9

#	Article	IF	Citations
55	Evaluation of the Interaction between Long Telomeric DNA and Macrocyclic Hexaoxazole (6OTD) Dimer of a G-quadruplex Ligand. Molecules, 2013, 18, 4328-4341.	3.8	30
56	JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells. Journal of Antibiotics, 2012, 65, 373-375.	2.0	5
57	HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature, 2012, 489, 313-317.	27.8	488
58	Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb. Clinical Cancer Research, 2012, 18, 1268-1280.	7.0	105
59	A Caged Ligand for a Telomeric Gâ€Quadruplex. ChemBioChem, 2012, 13, 774-777.	2.6	25
60	Fission Yeast Pot1 and RecQ Helicase Are Required for Efficient Chromosome Segregation. Molecular and Cellular Biology, 2011, 31, 495-506.	2.3	13
61	Role of Acyl-CoA Synthetases in Glioma Cell Survival and Its Therapeutic Implication. , 2011, , 337-340.		0
62	Tankyrases. , 2011, , 3604-3606.		0
63	Tankyraseâ€1 assembly to large protein complexes blocks its telomeric function. FEBS Letters, 2010, 584, 3885-3890.	2.8	4
64	ãƒ†ãƒãƒ¡ã‚¢ãƒ†ãƒãƒ¡ãƒ¬ãƒ¼ãƒ¼ã‚¹ã•ã–ã¥ãŠ—è…«ç˜ç™‚æ³•. Kagaku To Seibutsu, 2010, 48, 713-719.	0.0	0
65	Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth. Molecular Pharmacology, 2010, 78, 846-854.	2.3	41
66	TRF1 Mediates Mitotic Abnormalities Induced by Aurora-A Overexpression. Cancer Research, 2010, 70, 2041-2052.	0.9	26
67	Expression of Mutant RPA in Human Cancer Cells Causes Telomere Shortening. Bioscience, Biotechnology and Biochemistry, 2010, 74, 382-385.	1.3	16
68	A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochemical and Biophysical Research Communications, 2010, 394, 569-573.	2.1	41
69	Generation of Induced Pluripotent Stem Cells from Human Terminally Differentiated Circulating T Cells. Cell Stem Cell, 2010, 7, 11-14.	11.1	547
70	Visualization of G-quadruplexes by using a BODIPY-labeled macrocyclic heptaoxazole. Organic and Biomolecular Chemistry, 2010, 8, 2749.	2.8	61
71	Role of Insulin-Like Growth Factor Binding Protein 2 in Lung Adenocarcinoma. American Journal of Pathology, 2010, 176, 1756-1766.	3.8	36
72	Acylâ€CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Science, 2009, 100, 1556-1562.	3.9	62

#	Article	IF	Citations
73	Therapeutic Targets and Drugs III: Tankyrase 1, Telomere-Binding Proteins, and Inhibitors. , 2009, , 281-291.		0
74	Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation. Experimental Cell Research, 2008, 314, 1115-1124.	2.6	9
75	ATP Citrate Lyase: Activation and Therapeutic Implications in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2008, 68, 8547-8554.	0.9	326
76	HnRNP A3 binds to and protects mammalian telomeric repeats in vitro. Biochemical and Biophysical Research Communications, 2007, 358, 608-614.	2.1	27
77	Cross-species difference in telomeric function of tankyrase 1. Cancer Science, 2007, 98, 850-857.	3.9	28
78	Evaluation of Tankyrase Inhibition in Whole Cells. Methods in Molecular Biology, 2007, 405, 133-146.	0.9	7
79	The telomeric PARP, tankyrases, as targets for cancer therapy. British Journal of Cancer, 2006, 94, 341-345.	6.4	88
80	Cancer therapy targeting the telomere maintenance system. Drug Delivery System, 2006, 21, 24-31.	0.0	2
81	Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell, 2005, 7, 25-37.	16.8	160
82	Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13844-13849.	7.1	102
83	Functional Subdomain in the Ankyrin Domain of Tankyrase 1 Required for Poly(ADP-Ribosyl)ation of TRF1 and Telomere Elongation. Molecular and Cellular Biology, 2004, 24, 1944-1955.	2.3	83
84	The Telomeric Poly(ADP-ribose) Polymerase, Tankyrase 1, Contains Multiple Binding Sites for Telomeric Repeat Binding Factor 1 (TRF1) and a Novel Acceptor, 182-kDa Tankyrase-binding Protein (TAB182). Journal of Biological Chemistry, 2002, 277, 14116-14126.	3.4	129
85	Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Molecular Cancer Therapeutics, 2002, 1, 657-65.	4.1	99
86	Pim-1 Negatively Regulates the Activity of PTP-U2S Phosphatase and Influences Terminal Differentiation and Apoptosis of Monoblastoid Leukemia Cells. Archives of Biochemistry and Biophysics, 2001, 390, 9-18.	3.0	41
87	ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene, 1999, 18, 173-180.	5.9	169
88	Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. Oncogene, 1999, 18, 1277-1283.	5.9	30
89	Hypoxia Up-Regulates Telomerase Activity via Mitogen-Activated Protein Kinase Signaling in Human Solid Tumor Cells. Biochemical and Biophysical Research Communications, 1999, 260, 365-370.	2.1	90
90	Apoptosis resistance in tumor cells. Cytotechnology, 1998, 27, 293-308.	1.6	5

#	Article	IF	Citations
91	2-deoxyglucose inhibits chemotheapeutic drug-induced apoptosis in human monocytic leukemia U937 cells ith inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. , 1998, 76, 86-90.		16
92	Telomerase Inhibition, Telomere Shortening, and Senescence of Cancer Cells by Tea Catechins. Biochemical and Biophysical Research Communications, 1998, 249, 391-396.	2.1	226
93	Functional Involvement of PTP-U2L in Apoptosis Subsequent to Terminal Differentiation of Monoblastoid Leukemia Cells. Journal of Biological Chemistry, 1998, 273, 21187-21193.	3.4	20
94	Apoptosis resistance in tumor cells. , 1998, , 293-308.		0
95	c-Jun NH2-terminal Kinase-mediated Activation of Interleukin-1Î² Converting Enzyme/CED-3-like Protease during Anticancer Drug-induced Apoptosis. Journal of Biological Chemistry, 1997, 272, 4631-4636.	3.4	182
96	Inhibition of the Association with Nuclear Matrix of pRB, p70 and p40 Proteins Along with the Specific Suppression of c-MYC Expression by Geldanamycin, an Inhibitor of Src Tyrosine Kinase.. Journal of Antibiotics, 1995, 48, 1021-1026.	2.0	20
97	M-CSF gene transduction in multidrug-resistant human cancer cells to enhance anti-P-glycoprotein antibody-dependent macrophage-mediated cytotoxicity. International Journal of Cancer, 1993, 54, 851-857.	5.1	20
98	T Cell Receptor-Extracellular Constant Regions as Hetero-Cross-Linkers for Immunoglobulin Variable Regions. Journal of Biochemistry, 1993, 113, 687-691.	1.7	4
99	Mouseâ€Human Chimeric Antibody MH171 against the Multidrug Transporter Pâ€Glycoprotein. Japanese Journal of Cancer Research, 1992, 83, 515-521.	1.7	11